Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Investing.com - Bernstein SocGen Group has reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ: REGN) with a price target of $750.00.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Investing.com - JPMorgan has maintained its Overweight rating and $800.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN) ahead of the company’s second-quarter earnings report. The ...

Investing.com - TD Cowen has reiterated a Buy rating and $800.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN), a prominent biotech player with a $58.1 billion market cap, following FDA ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

Regeneron launches a $200 million matching donation program for Good Days’ Retinal Disease Fund to enhance patient access to medicines.